catalyx space | $5,400,000 | (Nov 4, 2025)
mimic(SWITZERLAND) | $160,000,000 | (Nov 4, 2025)
xMEMS | $21,000,000 | (Nov 4, 2025)
Certified by Founder
Lodge
DiogenX
start up
France
- Marseille
- 11/05/2023
- Series A
- $30,056,125
DiogenX is a preclinical stage biotech company committed to a single mission: to discover and develop innovative biologics as new therapeutics options for millions of Diabetic patients around the world.
Our lead program, originating from Dr Patrick Collombat’s laboratory, is based on a new approach targeting beta-cell failure throughout the stimulation of beta-cell functional recovery in diabetes. This novel mode of action will provide a unique solution to rebalance glucose/insulin homeostasis and thus offer clear clinically meaningful benefits.
DiogenX is headquartered in Marseille, with labs in Nice (France).
- Industry Biotechnology
- Website https://diogenx.com/
- LinkedIn https://www.linkedin.com/company/diogenx/
Zeeg | $1,265,935 | (Nov 4, 2025)
Cephia AI | $4,000,000 | (Nov 4, 2025)
Ornn | $5,700,000 | (Nov 4, 2025)
Helex | $3,500,000 | (Nov 4, 2025)
Hullbot | $16,000,000 | (Nov 4, 2025)
Indomo | $25,000,000 | (Nov 4, 2025)
AUI™ (Augmented Intelligence) | $20,000,000 | (Nov 4, 2025)
Popai Health | $11,000,000 | (Nov 4, 2025)